Context Therapeutics Inc. (CNTX)
(Real Time Quote from BATS)
$2.17 USD
+0.05 (2.36%)
Updated Jul 22, 2024 01:14 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
CNTX 2.17 +0.05(2.36%)
Will CNTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CNTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CNTX
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?
Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice
CNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
Other News for CNTX
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in SightÂ
Context Therapeutics files to sell 64.52M shares of common stock for holders
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Context Therapeutics initiated with bullish view at Piper Sandler, here's why